文献速递腹部技术与安全CTMRUSPET

影像学方法诊断胰腺导管腺癌:敏感度、特异度与诊断准确性的系统评价与Meta分析

Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy.
PubMed 文献 · Eur J Radiol · 2017-04-24

该系统评价纳入52项研究共5399例患者(其中3567例为胰腺导管腺癌),采用比例Meta分析分别汇总MRI、CT、PET、超声内镜及经腹超声诊断胰腺导管腺癌的敏感度、特异度与诊断准确性。结果显示除PET外,各 modality 的95%置信区间相互重叠;结论认为除PET外各方法诊断胰腺导管腺癌的效能相当。

要点

  • MRI诊断胰腺导管腺癌的敏感度93%、特异度89%、诊断准确性90%。
  • 经腹超声特异度最高(94%),PET特异度最低(70%)。
  • 除PET外,各影像方法诊断胰腺导管腺癌的95%置信区间相互重叠。

核心结论

  • 该系统评价结论认为,除PET外,所评价的各影像学方法在诊断胰腺导管腺癌时95%置信区间相互重叠。

研究设计与样本

  • 系统评价与比例Meta分析,纳入52项报告MRI、CT、PET、超声内镜或经腹超声诊断胰腺导管腺癌敏感度、特异度和/或诊断准确性的研究。
  • 共纳入5399例患者,其中3567例为胰腺导管腺癌。

诊断标准与关键数值

  • MRI诊断胰腺导管腺癌的敏感度93%(95%CI 88-96)、特异度89%(95%CI 82-94)、诊断准确性90%(95%CI 86-94)。
  • CT诊断胰腺导管腺癌的敏感度90%(95%CI 87-93)、特异度87%(95%CI 79-93)、诊断准确性89%(95%CI 85-93)。
  • PET诊断胰腺导管腺癌的敏感度89%(95%CI 85-93)、特异度70%(95%CI 54-84)、诊断准确性84%(95%CI 79-89)。
  • 超声内镜诊断胰腺导管腺癌的敏感度91%(95%CI 87-94)、特异度86%(95%CI 81-91)、诊断准确性89%(95%CI 87-92)。
  • 经腹超声诊断胰腺导管腺癌的敏感度88%(95%CI 86-90)、特异度94%(95%CI 87-98)、诊断准确性91%(95%CI 87-93)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Pancreatic cancer, primarily pancreatic ductal adenocarcinoma (PDAC), accounts for 2.4% of cancer diagnoses and 5.8% of cancer death annually. Early diagnoses can improve 5-year survival in PDAC. The aim of this systematic review was to determine the sensitivity, specificity and diagnostic accuracy values for MRI, CT, PET&PET/CT, EUS and transabdominal ultrasound (TAUS) in the diagnosis of PDAC.

METHODS: A systematic review was undertaken to identify studies reporting sensitivity, specificity and/or diagnostic accuracy for the diagnosis of PDAC with MRI, CT, PET, EUS or TAUS. Proportional meta-analysis was performed for each modality.

RESULTS: A total of 5399 patients, 3567 with PDAC, from 52 studies were included. The sensitivity, specificity and diagnostic accuracy were 93% (95% CI=88-96), 89% (95% CI=82-94) and 90% (95% CI=86-94) for MRI; 90% (95% CI=87-93), 87% (95% CI=79-93) and 89% (95% CI=85-93) for CT; 89% (95% CI=85-93), 70% (95% CI=54-84) and 84% (95% CI=79-89) for PET; 91% (95% CI=87-94), 86% (95% CI=81-91) and 89% (95% CI=87-92) for EUS; and 88% (95% CI=86-90), 94% (95% CI=87-98) and 91% (95% C=87-93) for TAUS.

CONCLUSION: This review concludes all modalities, except for PET, are equivalent within 95% confidence intervals for the diagnosis of PDAC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Toft J, Hadden WJ, Laurence JM, et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol. 2017. PMID: 28624015. doi:10.1016/j.ejrad.2017.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。